Latest Investor Updates News

NH3 Clean Energy updates investors on the WAH2 clean ammonia project, highlighting strong market potential, strategic partnerships, and robust project economics as it moves toward a Final Investment Decision.

Vinyl Group Ltd reported a striking 190% revenue increase for FY2025 but remains deep in the red with a $15.8 million loss. The company’s recent acquisitions and ongoing audit spotlight a pivotal moment for its future.

Rhythm Biosciences has significantly reduced its annual loss by 44%, boosted by a 91% rise in other income, while launching a new wholly owned subsidiary, RHY GeneType Pty Ltd.

The Calmer Co. International Limited reported a strong revenue increase of 88% for the year ended June 2025, yet the company still recorded a net loss of nearly $4 million, with no dividends declared.

Island Pharmaceuticals reported a $3.92 million loss for FY2025 despite an 86% increase in income, with no dividends declared.

Far Northern Resources has confirmed a combined JORC-compliant gold resource of over 117,000 ounces across its Northern Territory and Queensland projects, with Phase 2 drilling at Bridge Creek set to commence in September 2025.

ImpediMed Limited has posted a 23% increase in revenue for the 2025 financial year, yet its net loss widened by 17%, with no dividends declared. The company’s financials, audited by Ernst & Young, reveal a complex picture of growth paired with escalating costs.

Frontier Energy Limited reported a sharp 90% increase in net loss to $210,593 for the half year ended June 2025, with no revenue recorded and no dividends declared.

Nyrada Inc. reported a sharp 25% decline in revenues alongside a 248% surge in net losses for the fiscal year ending June 2025, signaling mounting financial pressures for the pharmaceutical developer.

DUG Technology’s latest financials reveal a modest revenue decline and a widening net loss for the fiscal year ended June 2025, with no dividends declared.

Fiducian Group Limited has reported a solid 23.5% rise in net profit for the 2025 financial year, alongside a 10.6% increase in revenue and a higher fully franked final dividend of 24.7 cents per share.

Pro Medicus Limited has reported a robust FY25 with revenue climbing nearly 32% and net profit up 39%, prompting a significant dividend increase.